A different operating system, not a broken one. But the neuroinflammation, sensory overwhelm, and oxidative stress that often come with it — those can be addressed.
There is no standard medical treatment for autism itself. Behavioral interventions — ABA therapy, speech therapy, occupational therapy — remain the primary approach. Medications target specific symptoms: risperidone or aripiprazole for irritability, SSRIs for anxiety, stimulants for attention. None address underlying neuroinflammation or cerebral hypoperfusion, which research increasingly identifies as common physiological features in autism spectrum conditions.
Rossignol et al. (2009) published a landmark multicenter, randomized, double-blind controlled trial in BMC Pediatrics. Children with autism receiving HBOT at 1.3 ATA showed significant improvements in overall functioning, receptive language, social interaction, and eye contact compared to controls. This remains the largest controlled HBOT-autism trial to date, with 62 children.1
Rossignol and Rossignol (2006) reviewed the rationale for HBOT in autism in Medical Hypotheses, documenting evidence that children with autism frequently exhibit cerebral hypoperfusion, neuroinflammation, and mitochondrial dysfunction — all conditions responsive to increased oxygen delivery. SPECT studies show reduced blood flow in temporal and frontal lobes.2
Bent et al. (2012) conducted a controlled trial published in the Journal of Autism and Developmental Disorders examining HBOT at 1.3 ATA in children with autism. While the primary behavioral outcome was not significant between groups, both groups improved, and the authors noted that the slight pressurization in the control group may itself have been therapeutic, complicating the comparison.3
Leisman et al. (2014) reviewed photobiomodulation's potential for neurodevelopmental conditions in Frontiers in Systems Neuroscience, noting that transcranial NIR light can modulate cortical excitability and improve functional connectivity — both relevant to autism, where abnormal connectivity patterns are a core finding.4
Ceranoglu et al. (2022) published a pilot study in the Journal of Psychiatric Research examining transcranial photobiomodulation at 810 nm in adults with autism. Participants showed improvements in social communication, anxiety, and irritability measures after an eight-week protocol, with no adverse effects reported.5
Hamblin (2018) detailed in BBA Clinical how near-infrared light reduces neuroinflammation by downregulating pro-inflammatory cytokines and enhancing mitochondrial ATP production — directly addressing two of the most commonly documented physiological abnormalities in autism.6